Bambusa Therapeutics, Inc., a clinical-stage biotech advancing next-generation bispecific antibodies, announced two landmark achievements for its lead candidate, BBT001.
Strong Phase I Results in Healthy Volunteers
At the EADV 2025 Congress, Bambusa presented highly positive data from the single ascending dose portion of its ongoing Phase I trial. Key findings included:
- Favorable safety across all dose levels with no dose-limiting adverse events.
- Best-in-class pharmacokinetics with a ~33-day half-life, enabling flexible dosing.
- Rapid, complete, and sustained IL-4Rα binding and pSTAT6 inhibition through Week 8+.
- Unprecedented reduction in TARC levels—dose-dependent, deep, and sustained through Week 8+.
“These results provide the first clinical evidence of BBT001’s potential to become a best-in-disease biologic in atopic dermatitis,”
- Thang Ho, Ph.D., SVP of Development Sciences.
He added that the data suggest synergy between IL-4Rα and IL-31 inhibition, potentially delivering faster onset and deeper relief for patients with type 2 inflammatory skin diseases.
First Patient Dosed in Atopic Dermatitis
This week, Bambusa reached its next milestone: the first patient with moderate-to-severe atopic dermatitis has been dosed in the ongoing Phase I trial.
“Achieving patient dosing within 16 months of our inception underscores our pace of execution. We now feel a deep responsibility to accelerate development, generate proof-of-concept data, and redefine the standard of care.”
- Shanshan Xu, M.D., Ph.D., CEO and Founder.
About the BBT001-001 Trial
- Design: Randomized, placebo-controlled, single- and multiple-ascending-dose.
- Participants: Healthy volunteers and adults with moderate-to-severe atopic dermatitis.
- Endpoints: Safety, tolerability, PK, immunogenicity, pharmacodynamics, and early clinical activity.
- Status: Enrollment ongoing; additional data expected in 2026.
About BBT001
BBT001 is a first-in-class, half-life extended bispecific antibody engineered to block IL-4Rα and IL-31 signaling. The dual mechanism is designed to address type 2 inflammation and directly target itch pathways, offering faster and more durable relief.
The molecule has already shown a favorable safety profile and strong PK in healthy volunteers, supporting advancement into patient studies.
About Bambusa Therapeutics
Bambusa Therapeutics is a Boston-based clinical-stage biotech focused on next-generation bispecific antibodies for chronic diseases. Its pipeline includes:
- BBT001 – Targeting IL-4Rα and IL-31, now in Phase I for atopic dermatitis and type 2 inflammatory skin diseases.
- BBT002 – Targeting IL-4Rα and IL-5, in Phase I for COPD, asthma, and CRSwNP.
- BBT003/BBT004 – Preclinical programs in gastroenterology and rheumatology.
Powered by its antibody engineering platform with half-life extension and subcutaneous delivery, Bambusa aims to deliver best-in-disease impact across multiple therapeutic areas.
